68047-06-3
基本信息
4-羟基他莫昔芬
(Z)-4-羟基三苯氧胺
4-羟基三苯氧胺 10MG
4-羟基三苯氧胺(Z异构体)
4-羟基三苯氧胺(Z异构体和E
4-羟基三苯氧胺(Z异构体≥7
4-羟基三苯氧胺(Z异构体≥70%)
4-羟基三苯氧胺(Z异构体和E异构体)
(Z)-4-(1-[4-(二甲氨基乙氧基)苯基]-2-苯基-1-丁烯基)苯酚
C05011
ici79,280
(Z)-4-OHT
hydroxytamoxifen
4-HYDROXYTAMOXIFEN
TAMOXIFEN, 4-HYDROXY-
cis-4-Hydroxytamoxifen
trans-4-Hydroxytamoxifen
See H9711, H9712, or H9716
物理化学性质
| 熔点 | 105-107°C |
| 沸点 | 513.45°C (rough estimate) |
| 密度 | 1.1005 (rough estimate) |
| 折射率 | 1.6000 (estimate) |
| 储存条件 | 2-8°C |
| 储存条件 | 2-8°C |
| 溶解度 | 95% ethanol: 20 mg/mL |
| 溶解度 | 95%乙醇：20 mg/mL |
| 酸度系数(pKa) | 10.35±0.15(Predicted) |
| 形态 | powder |
| 颜色 | white |
| 稳定性 | 稳定的。存放干燥通风处。与强氧化剂不相容。 |
| InChI | InChI=1S/C26H29NO2/c1-4-25(20-8-6-5-7-9-20)26(21-10-14-23(28)15-11-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25- |
| InChIKey | TXUZVZSFRXZGTL-OCEACIFDSA-N |
| SMILES | C1(O)=CC=C(/C(/C2=CC=C(OCCN(C)C)C=C2)=C(/C2=CC=CC=C2)\CC)C=C1 |
| CAS 数据库 | 68047-06-3 |
安全数据
| 危险性符号(GHS) |    GHS07,GHS08,GHS09 |
| 警示词 | 危险 |
| 危险性描述 | H302-H350-H360FD-H410 |
| 防范说明 | P201-P202-P264-P273-P301+P312-P308+P313 |
| 危险品标志 | Xn |
| 危险类别码 | 20/21/22-63 |
| 安全说明 | 22-23-36 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| RTECS号 | SL1210000 |
4-羟基三苯氧胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-16950R | 4-羟基三苯氧胺 4-Hydroxytamoxifen (Standard) | 68047-06-3 | 5 mg | 1800元 |
| 2026/09/15 | HY-16950 | 4-羟基三苯氧胺 4-Hydroxytamoxifen | 68047-06-3 | 1 mg | 320元 |
| 2026/09/15 | HY-16950R | 4-羟基三苯氧胺 4-Hydroxytamoxifen (Standard) | 68047-06-3 | 10 mg | 2950元 |
常见问题列表
|
Estrogen receptor 3.3 nM (IC 50 ) |
CRISPR/Cas9
|
4-Hydroxytamoxifen (Monohydroxytamoxifen) is a selective oestrogen receptor antagonist, with an IC 50 of 3.3 nM for the [ 3 H]oestradiol binding to oestrogen receptor. 4-Hydroxytamoxifen (10, 100 nM) enables to inhibit the binding of [ 3 H]oestradiol to the human 8 S oestrogen receptor. 4-Hydroxytamoxifen activates intein-linked inactive Cas9, reduces off-target CRISPR-mediated gene editing. In human cells, conditionally active Cas9s modify target genomic sites with up to 25-fold higher specificity than wild-type Cas9.
4-Hydroxytamoxifen (0.2, 1 and 5 μg/day, p.o.) causes a dose-related decrease in uterine wet weight of immature rats. 4-Hydroxytamoxifen (6 μg/0.1 mL sesame oil/day, s.c.) effectively attenuates methamphetamine-induced nigrostriatal dopamine depletions in bothsexes of intact and gonadectomized C57BL/6 J mice. 4-Hydroxytamoxifen does not alter the dopamine content levels in the striatum.